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Following the amendment of the Pharmaceutical Affairs Law in Japan in 2003 researchers
were permitted to begin investigator-initiated trials (IITs). In subsequent years, however, the
number of IITs remained low. In other countries in Asia as well as in Europe, North America,
and South Africa, the number of IITs has increased over the past decade. The differences in
the characteristics of IITs between Japan and other countries are unknown. Some studies
have analyzed the characteristics of all clinical trials according to registry databases, but
there has been less research focusing on IITs.
Aims
The purpose of this study is to analyze the characteristics of IITs in the ClinicalTrials.gov
registry and in the three Japanese registries, to identify differences in IITs between Japan
and other countries.
Methods
Using Thomson Reuters Pharma™, trials sponsored by academia and government as IITs
in 2010 and registered in ClinicalTrials.gov were identified. IITs from 2004 to 2012 in Japan
were identified in the three Japanese registries: the University Hospital Medical Information
Network Clinical Trials Registry, the Japan Pharmaceutical Information Center Clinical Tri-
als Information, and the Japan Medical Association Center for Clinical Trials, Clinical Trials
Registry. Characterization was made of the trial purposes, phases, participants, masking,
arms, design, controls, and other data.
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Results
New and revised IITs registered in ClinicalTrials.gov during 2010 averaged about 40% of all
sponsor-identified trials. IITs were nearly all early-phase studies with small numbers of par-
ticipants. A total of 56 Japanese IITs were found over a period of 8 years, and these were
also almost nearly all early-phase studies with small numbers of participants.
Conclusion
There appear to be no great differences between Japan and other countries in terms of
characteristics of IITs. These results should prompt a new review of the IIT environment in
Japan.
Introduction
Until 2003, investigators in Japan could not conduct clinical trials individually, whether to
investigate a new medicine or a new application of approved drugs or even to research theories
or promising treatments. Companies carried out such studies and then submitted an investiga-
tional new drug (IND) application to the Ministry of Health, Labour, and Welfare (MHLW).
Amendment of the Pharmaceutical Affairs Law in July 2002 permitted investigators to apply
for INDs in July 2003, thus marking the start of investigator-initiated trials (IITs) in Japan.
However, the number of IIT applications for INDs remained quite small at about 60 from 2004
to 2010 [1]. About half of these were trials for new applications of an approved drug, using
funding schemes for the Clinical Trial Grant Program of the Japan Medical Association Center
for Clinical Trials (JMACCT) [2]. The other half was trials proposed by the author, to investi-
gate a new drug or device in an early-phase study with a small number participants and using
government funding schemes or institutional budgets. The reasons for the small number of
IITs during this period include few funding opportunities and a poor quality assurance struc-
ture [3]. A review of ClinicalTrials.gov, one of the largest open registries of publicly and pri-
vately supported clinical trials worldwide, showed that there were over 7,000, registered studies
from 2000 to 2010 sponsored by the United States National Institutes of Health (NIH) and US
government agencies and excluding industry, which includes the majority of IITs [4]. These
results highlight a large difference between Japan and other countries in terms of numbers of
IITs. Key factors that may contribute to increasing IITs in Japan might be found by investigat-
ing IITs registered in ClinicalTrials.gov. Califf et al. found that trials registered in
ClinicalTrials.gov exhibited heterogeneity in their methodological approaches, and that spon-
sored-identified trials accounted for a total of 40% of registered trials from 2007 to 2010 [4].
However, no studies have focused on IITs sponsored by academic or government institutions.
Thus, the purpose of this study is to identify differences between Japan and other countries
through analyzing the characteristics of trials sponsored by academia or government in the
ClinicalTrials.gov database and sponsored-identified IITs in the three Japanese registries
database.
The ClinicalTrials.gov registry was established in 2000 by the National Library of Medicine
on behalf of the NIH. ClinicalTrials.gov is a publicly available clinical trial registry and results
database. Data are self-reported by sponsors via a web-based system. Any sponsor, principal
investigator, or other person or organization with primary responsibility for a trial can register
trials in the database. The registry includes mandatory and optional data elements such as the
trial purpose, phase, enrolled participants, age group, participant sex, masking, trial assign-
ment, number of arms, treatment allocation, and trial control groups. ClinicalTrials.gov is a
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not only an integrated database for clinical trials but also a useful tool to visualize trends in cur-
rent trials. In 2004, the International Committee of Medical Journal Editors (ICMJE) initiated
a policy requiring registration of clinical trials as a prerequisite for publication [5]. In the
United States, the Food and Drug Administration Amendment Acts of 2007 requires sponsors
to register clinical trials in a database [6]. This amendment resulted in a sharp increase in the
number of trials registered in ClinicalTrials.gov.
In Japan, the University Hospital Medical Information Network Clinical Trials Registry
(UMIN-CTR) was begun in June 2005, as the first Japanese registry accepted by the ICMJE.
The second registry site, the Japan Pharmaceutical Information Center Clinical Trials Informa-
tion (JapicCTI), was established in July 2005 and the third, the Japan Medical Association Cen-
ter for Clinical Trials, Clinical Trials Registry (JMACCT CTR), in December 2005 [7]. The
three registries are publicly available. Data are self-reported by sponsors. All three Japanese
registries include elements included in ClinicalTrials.gov, such as trial purpose, study type,
study design, phase, enrolled participants, age group, participant sex, trial masking, trial assign-
ment, number of arms, treatment allocation, and trial control groups. Under its funding rules
of 2009, sponsors must register clinical trials funded by the MHLW in a trial database.
The methods used in this study are described in Section 2 (Materials and Methods). Section
3 (Results) elaborates all analyzed trials for 2010 and characterization according to three thera-
peutic areas. Discussion is presented in Section 4 (Discussion) and conclusions in Section 5
(Conclusion).
Materials and Methods
Data of new or revised trials registered with ClinicalTrials.gov in 2010 were collected through
Thomson Reuters Pharma™, a data source for pharmaceutical information owned by Thomson
Reuters, which enables clinical trial data to be downloaded as a whole. Data of new IITs regis-
tered from 2004 to 2012 in Japan were collected via the UMIN-CTR, JapicCTI, and JMACCT
CTR registry sites.
Data set
Over 100,000 clinical trials were registered in ClinicalTrials.gov during 2010. Here, a total
88,819 trials were chosen via Thomson Reuters Pharma, by focusing on the main therapeutic
areas including cardiovascular, endocrine, gastrointestinal, immunological, infectious, inflam-
matory, neoplasm, neurological, and respiratory diseases. This data set was downloaded from
Thomson Reuters Pharma, between 25 and 28 March 2011, to facilitate aggregate analysis.
Data were included in two XML data files comprising 88,819 clinical trials in total and 1,943
sponsor-identified trials, grouped according to three therapeutic areas: cardiovascular diseases,
brain diseases within neurological diseases, and endocrine tumors within neoplasms. The rea-
son for choosing these three disease areas is that it was of interest to the author to determine
trends of trials in these treatment areas, having worked as a clinical trial manager with clini-
cians in these specialties. A total 38,003 new or revised trials, registered from 1 January to 31
December 2010, were extracted from the total 88,819 trials. Extracted trials were further cate-
gorized into sponsor-identified and non-sponsor-identified trials.
In line with the organization authority file of Thomson Reuters Pharma, sponsors were
defined by organization type: academic institution, government, company, collective invest-
ment, government department or agency, market participant, non-government organization,
supranational, or unknown. For instance, if the lead sponsoring organization was a university
or research institute, the organization type was categorized as an academic institution. If the
lead sponsor was a private company, small- to medium-sized enterprise, or start-up company,
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this was categorized as a company. Nearly 70% of all trials had a currently identified sponsor-
ing organization in accordance with the organization authority file. Sponsor-identified trials
were then divided into two categories, academia and government (A&G) or industry; all A&G
sponsor-identified trials (A&G trials) here were IITs. If trials included both an academic insti-
tution and industry outfit as a sponsor and a collaborator, they were defined as sponsored by
both. Data of A&G trials that had been classified as neurological diseases and neoplasms were
regrouped into brain diseases and endocrine tumors, respectively. Within these therapeutic
specialty data sets, a few data elements were missing because of limitations in the data set or
logistical problems in obtaining analyzable information. For this regrouping, an index by
Thomson Reuters Pharma was used to create specialty data sets.
A data set of IITs conducted under Good Clinical Practice (GCP) guidelines in Japan was
collected using information in the UMIN, JAPIC or JMACCT registries. An IIT was defined
as an IND application trial conducted by investigators, based on governmental funding pro-
gram information, clinical trial information of the MHLW and JMACCT, or clinical trial
information on websites of universities, hospitals, and research institutes. The IITs were also
found on either the UMIN-CTR, JapicCTI, or JMACCT CTR sites. Because the number of
trials in only 2010 was too small to compare with trials in ClinicalTrials.gov in the same year,
all IITs in Japan during an 8-year period between January 2004 and March 2012 were ana-
lyzed. These data were collected from 1 April 2011 to 31 March 2012 and comprised a total
of 56 trials.
Analytical methods
From the ClinicalTrials.gov database, the three main therapeutic areas of clinical trial data
(brain diseases within neurological diseases, cardiovascular diseases, and endocrine tumors
within neoplasms) were characterized and analyzed, using a model containing 11 characteris-
tics: study type (interventional or observational); purpose (treatment, basic science, diagnostic,
health services, natural history, prevention, screening, supportive care, training, and other);
phase (0, 1, 1/2, 1b, 2, 2/3, 2a, 2b, 3, 3b, 4); number of enrolled participants (<5, 5–10, 10–20,
20–50, 50–100, 100–200, 200–500, and>500); trial age group (children, adults, older adults, or
all ages); trial masking (open-label, single-blind, or double-blind); trial assignment (single, par-
allel, crossover, or factorial); number of arms (1, 2, 3, 4, 5, or 6); trial allocation (randomized or
non-randomized); trial control (placebo, active, dose comparison, historical, or uncontrolled);
and sex of the study population (male, female, or both).
All Japanese IIT from 2004 to 2012 were characterized and analyzed, using a model contain-
ing 11 characteristics: study type (interventional or observational); purpose (treatment, preven-
tion, pharmacokinetics, and others); phase (1, 1/2, 2, 2/3, 3 or 4); number of enrolled
participants (<5, 5–10, 10–20, 20–50, 50–100, 100–200, 200–500 or>500); trial age group
(children, adults, older adults, or all ages); trial masking (open-label, single-blind, or double-
blind); trial assignment (single, parallel or factorial); number of arms (1, 2, 3, 4 or 5); trial allo-
cation (randomized or non-randomized); trial control (placebo, active, dose comparison, his-
torical or uncontrolled); and sex (male, female, or both).
Cross analyses were then performed between trial purpose and phase, between trial purpose
and participants, and between trial phase and participants using ClinicalTrials.gov data and
Japanese registry data, respectively.
All assessments are described as a number or a percentage. Statistical analysis software was
not used in this study.
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Results
A total 38,003 of 88,819 new or revised clinical trials registered in ClinicalTrials.gov in 2010
were extracted (Table 1). Of these, 29,200 (76.8%) were identified as trials sponsored by an
organization. There were 11,737 (40.2%) A&G trials. By contrast, industry-sponsored trials
accounted for 19,638 (67.3%). Between 5.5% and 9.2% of trials for each therapeutic group were
A&G and industry-sponsored trials. When examining all trials registered in ClinicalTrials.gov
in 2010, neoplasm trials had the highest ratios, accounting for 4,705 of 8,132 (57.9%) of A&G
trials. The highest number of industry-sponsored trials was for inflammatory disease, with
1,847/2,169 (85.2%).
The number of A&G trials in the three therapeutic areas investigated was 385, 559, and 959
for brain disease, cardiovascular disease, and endocrine tumors, respectively (Table 2). The
study type was interventional for all three therapeutic specialties, and the purpose was mostly
treatment. The number of prevention trials for cardiovascular disease, 78/599 (13%), was
higher than for the other two areas. Phases 0 through 2 accounted for over 60% and 80% for
brain diseases and endocrine tumors trials, respectively; however, these phases represented
only about 35% of cardiovascular trials. The category of 20–50 enrolled participants was most
frequent for the three therapeutic areas: 125/385 (32.5%), 147/599 (24.5%), and 365/959
(38.1%) for brain disease, cardiovascular disease, and endocrine tumors, respectively. Interest-
ingly, cardiovascular disease trials had the largest sized trials, with 200–500 (83/599, 13.9%)
and>500 (75/599, 12.5%) enrolled participants. The adult age group was the most frequent of
all groups, but there were 67/385 (17.4%) brain disease trials conducted in children. Masking
was completely different among the three trial areas. Open-label was the most frequent for
brain disease and endocrine tumor trials, with 165/385 (42.9%) and 598/959 (62.4%), respec-
tively. However, double-blind was most prevalent in cardiovascular disease trials, with 275/599
(45.9%). Assignment also differed among the three therapeutic areas. In brain disease trials,
single and parallel groups accounted for 88/385 (22.9%) and 93/385 (24.2%), respectively, how-
ever, missing data represented about half of brain disease trials, or 187/385 (48.6%). In






























5779 2492 1781 71.5% 599 33.6% 1321 74.2% 7.8%
Endocrine
Disease
8166 3542 2819 79.6% 1072 38.0% 1933 68.6% 6.6%
Gastrointestinal
Disease
11451 4906 3772 76.9% 1372 36.4% 2660 70.5% 6.9%
Immunological
Disease
8879 3615 2870 79.4% 1110 38.7% 1968 68.6% 7.2%
Infection 9240 3775 2608 69.1% 793 30.4% 2022 77.5% 7.9%
Inﬂammatory
Disease
7156 2857 2169 75.9% 450 20.7% 1847 85.2% 5.9%
Neoplasm 22940 10077 8132 80.7% 4705 57.9% 4178 51.4% 9.2%
Neurological
Disease
7973 3537 2667 75.4% 907 34.0% 1908 71.5% 5.5%
Respiratory
Disease
7235 3202 2382 74.4% 729 30.6% 1801 75.6% 6.2%
Total 88819 38003 29200 76.8% 11737 40.2% 19638 67.3%
doi:10.1371/journal.pone.0148455.t001
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Table 2. Characteristics of A&G Studies Registered in ClinicalTrials.gov During 2010.
Brain Disease within Neurological
Disease (%) (n = 385)
Cardiovascular Disease
(%) (n = 599)
Endocrine Tumor within
Neoplasm (%) (n = 959)
Study Type Interventional 374 (97.1) 580 (96.8) 948 (98.9)
Observational 11 (2.9) 18 (3.0) 10 (1.0)
Missing 0 (0.0) 1 (0.2) 1 (0.1)
Purpose Treatment 337 (87.5) 460 (76.8) 890 (92.8)
Basic Science 3 (0.8) 12 (2.0) 3 (0.3)
Diagnostic 7 (1.8) 17 (2.8) 12 (1.3)
Health Services 1 (0.3) 0 (0.0) 0 (0.0)
Natural History 1 (0.3) 0 (0.0) 0 (0.0)
Other 0 (0.0) 4 (0.7) 1 (0.1)
Prevention 18 (4.7) 78 (13.0) 22 (2.3)
Screening 3 (0.8) 3 (0.5) 2 (0.2)
Supportive Care 8 (2.1) 8 (1.3) 18 (1.9)
Training 0 (0.0) 0 (0.0) 1 (0.1)
Missing 7 (1.8) 17 (2.8) 10 (1.0)
Phase Phase 0 1 (0.3) 5 (0.8) 4 (0.4)
Phase 1 75 (19.5) 32 (5.3) 192 (20.0)
Phase 1/2 42 (10.9) 32 (5.3) 97 (10.1)
Phase 2 116 (30.1) 87 (14.5) 479 (49.9)
Phase 2/3 10 (2.6) 24 (4.0) 7 (0.7)
Phase 3 33 (8.6) 82 (13.7) 122 (12.7)
Phase 4 34 (8.8) 134 (22.4) 6 (0.6)
Phase Not
Speciﬁed
74 (19.2) 200 (33.4) 52 (5.4)
Missing 0 (0.0) 3 (0.5) 0 (0.0)
Number of Enrolled
Participants
<5 5 (1.3) 8 (1.3) 13 (1.4)
5–10 10 (2.6) 9 (1.5) 15 (1.6)
10–20 55 (14.3) 47 (7.8) 66 (6.9)
20–50 125 (32.5) 147 (24.5) 365 (38.1)
50–100 85 (22.1) 125 (20.9) 242 (25.2)
100–200 38 (9.9) 89 (14.9) 84 (8.8)
200–500 29 (7.5) 83 (13.9) 49 (5.1)
>500 15 (3.9) 75 (12.5) 81 (8.4)
Missing 23 (6.0) 16 (2.7) 44 (4.6)
Trial Age Group Children (0–17 y) 67 (17.4) 37 (6.2) 11 (1.1)
Adults (18–65 y) 262 (68.1) 468 (78.1) 820 (85.5)
Older adults (66
+ y)
9 (2.3) 3 (0.5) 5 (0.5)
All ages 7 (1.8) 0 (0.0) 0 (0.0)
Missing 40 (10.4) 91 (15.2) 123 (12.8)
Trial Masking Open-label 165 (42.9) 212 (35.4) 598 (62.4)
Single-blind 11 (2.9) 47 (7.8) 5 (0.5)
Double-blind 99 (25.7) 275 (45.9) 49 (5.1)
Missing 110 (28.6) 65 (10.9) 307 (32.0)
Trial Assignment Single Group 88 (22.9) 95 (15.9) 282 (29.4)
Parallel 93 (24.2) 314 (52.4) 82 (8.6)
Crossover 15 (3.9) 58 (9.7) 8 (0.8)
(Continued)
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cardiovascular disease trials, parallel groups accounted for 314/599 (52.4%). In endocrine
tumor trials, single groups accounted for 282/959 (29.4%), but missing data accounted for 587/
959 (61.2%) trials. Trial arms were predominantly (with about 60%) one- and two-armed trials
among the three therapeutic areas. One-armed trials were the most frequent among brain dis-
ease and endocrine tumor trials, with 116/385 (30.1%) and 409/959 (42.6%), respectively. In
cardiovascular disease trials, two-armed trials accounted for 275/599 (45.9%). Allocation dif-
fered by specialty. Cardiovascular disease trials were mostly randomized, with 472/599
(78.8%), whereas brain disease and endocrine tumor trials were less so, with 142/385 (36.9%)
and 255/959 (26.6%), respectively. However, there were missing data for about 50% of trials for
the latter two specialties. The trial control was also different among these areas. Brain disease
and cardiovascular disease trials were mostly conducted using placebo controls, with 83/385
(21.6%) and 245/599 (40.9%), respectively. Endocrine tumor trials were mostly performed
using active controls, with 133/959 (13.9%). However, over 50% of brain disease and endocrine
tumor trials had missing data. Trials included both sexes, except for endocrine tumor trials;
half of these were for breast or ovarian cancers and therefore included only females.
According to cross-analysis between trial purposes and phases, most brain disease and
endocrine tumor trials were for treatment and from early phase through phase 2 (Fig 1). Car-
diovascular disease trials for the purpose of treatment showed two peaks, one for early phase
(phases 1 to 2) and another for late phase (phases 3 to 4) trials. In the cross-analysis between
trial purpose and participants, all three therapeutic areas were dominated by low enrollment
numbers (20–50 participants) and were for the purpose of treatment (Fig 2). Cross-analysis
Table 2. (Continued)
Brain Disease within Neurological
Disease (%) (n = 385)
Cardiovascular Disease
(%) (n = 599)
Endocrine Tumor within
Neoplasm (%) (n = 959)
Factorial 2 (0.5) 14 (2.3) 0 (0.0)
Missing 187 (48.6) 118 (19.7) 587 (61.2)
Number of Arms 1 116 (30.1) 92 (15.4) 409 (42.6)
2 96 (24.9) 275 (45.9) 145 (15.1)
3 14 (3.6) 52 (8.7) 35 (3.6)
4 7 (1.8) 21 (3.5) 11 (1.1)
5 1 (0.3) 1 (0.2) 3 (0.3)
6 1 (0.3) 4 (0.7) 2 (0.2)
Missing 150 (39.0) 154 (25.7) 354 (36.9)
Trial Allocation Randomized 142 (36.9) 472 (78.8) 255 (26.6)
Non-randomized 52 (13.5) 52 (8.7) 218 (22.7)
Missing 191 (49.6) 75 (12.5) 486 (50.7)
Trial Control Placebo Control 83 (21.6) 245 (40.9) 44 (4.6)
Active Control 39 (10.1) 131 (21.9) 133 (13.9)
Dose
Comparison
13 (3.4) 25 (4.2) 19 (2.0)
Historical
Control
4 (1.0) 6 (1.0) 21 (2.2)
Uncontrolled 24 (6.2) 41 (6.8) 73 (7.6)
Missing 222 (57.7) 151 (25.2) 669 (69.8)
Sex Female Only 8 (2.1) 34 (5.7) 468 (48.8)
Male Only 4 (1.0) 22 (3.7) 7 (0.7)
Both 373 (96.9) 543 (90.7) 484 (50.5)
doi:10.1371/journal.pone.0148455.t002
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Fig 1. Cross-analyses between trial purpose and phase in ClinicalTrials.gov. Curve areas represent the
number of trials across the phase and the trial purposes, for brain diseases, cardiovascular disease, and
endocrine tumors, respectively.
doi:10.1371/journal.pone.0148455.g001
Fig 2. Cross-analyses between trial purpose and participants in ClinicalTrials.gov. Curve areas
represent the number of trials across the participants and the trial purposes, for brain diseases,
cardiovascular disease, and endocrine tumor, respectively.
doi:10.1371/journal.pone.0148455.g002
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between trial phases and participants identified that A&G trials were nearly all early phase
(through phase 2) with fewer than 100 enrolled participants (Fig 3). However, in all three spe-
cialties, there were also some peaks in late-phase trials with large enrollment.
In Japan, IITs under GCP began in 2004. A total of 56 IITs were found over the 8 years from
January 2004 to March 2012 in the three Japanese registries (Fig 4). There were 29, 24, and
three IITs identified in the UMIN-CTR, JMACCT CTR, and JapicCTI registries, respectively.
The number of IITs subsequently showed a slight annual increase, despite decreasing for 2
Fig 3. Cross-analyses between trial participants and phase in ClinicalTrials.gov. Curve areas represent
the number of trials across the phase and the participants, for brain diseases, cardiovascular disease, and
endocrine tumor, respectively.
doi:10.1371/journal.pone.0148455.g003
Fig 4. Number of investigator-initiated trials in Japanese registries. Curve represents the number of
investigator-initiated trials from 2004 to 2012.
doi:10.1371/journal.pone.0148455.g004
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years between 2006 and 2007. Table 3 shows the characteristics of the 56 identified IITs,
analyzed according to the 11 categories. The study type was dominated by interventional for all
trials, and the purpose was mostly treatment. The number of prevention trials and pharmaco-
kinetics trials were as follows: four influenza vaccine studies, and three phase 1 and 1/2 studies
during the study period, respectively. Phases 1 to 2 accounted for around 50% of all trials, and
phase 3 trials represented 12/56 (21.4%). Studies in which the phase was not specified were the
mostly exploratory trials of medical devices. The category of 20–50 enrolled participants was
the most frequent, with 26/56 (46.4%). Trial age groups varied widely, but children, adults and
older adults were the groups most frequently represented, together accounting for 21/56
(37.5%). Open-label was the most frequent type of trials masking, with 42/56 (75.0%). Assign-
ment was predominantly single with 33/56 (58.9%) and parallel with 21/56 (35.7%). Trial arms
were mostly one-armed trials with 32/56 (57.1%) and two-armed trials with 19/56 (33.9%).
Allocation was dominated by non-randomized trials with 35/56 (62.5%), followed by random-
ized trials with 20/56 (35.7%). In terms of the trial control, uncontrolled studies were the most
prevalent with 33/56 (58.9%), followed by placebo-control with 7/56 (12.5%), active control
with 6/56 (10.7%), dose comparison with 7/56 (10.7%), and historical control with 4/56 (7.1%).
Most trials included both sexes nearly equally, except for female-only breast or ovarian cancer
trials and male-only trials for male hormonal disorders and pharmacokinetics.
Regarding cross-analysis between trial purposes and phases, most trials were for treatment
and from early phase through phase 2 (Fig 5). In the cross-analysis between trial purpose and
participants, trials were dominated by those with low enrollment numbers (up to 20–50 partici-
pants) and were for the purpose of treatment (Fig 6). Cross-analysis between trial phases and
participants identified that nearly all trials were early phase (through phase 2) with fewer than
100 enrolled participants (Fig 7). However, there were also some peaks in late-phase trials.
Discussion
To identify differences between Japan and other countries regarding IITs with academic or
government sponsors, this study investigated the characteristics of newly registered or revised
sponsor-identified trials in ClinicalTrials.gov in 2010, as compared with characteristics of
newly registered IITs in the UMIN-CTR, JapicCTI or JMACCT CTR registries from 2004 to
2012.
First, sponsor-identified trials represented over 75% of all trials registered with
ClinicalTrials.gov in 2010, and A&G trials accounted for about 40% of all sponsor-identified
trials. The number of A&G trials was lower than that of industry-sponsored trials. Interest-
ingly, each therapeutic area had different percentages of trials sponsored by A&G and industry.
Neoplasm trials had the most A&G trials with 57.9%, which represents efforts by academia to
develop new medicines, devices, and diagnoses for this therapeutic area. Conversely, inflamma-
tory disease trials had the least A&G trials at 20.7%, which might indicate that industry is more
interested in development in this area.
According to analyses of the three therapeutic areas investigated, A&G trials included pri-
marily small (<100 participants) and early-phase trials. This suggests that these trials are likely
to be broad, exploratory ones and very heterogeneous. Brain disease and endocrine tumor
areas had a concentration of early-phase trials and/or feasibility studies and were more often to
be open-label, single-arm studies. Interestingly, endocrine tumor studies were particularly
characterized by female-only trials for ovarian or breast cancer, which indicates an increasing
trend in the development of new ovarian and breast cancer treatments in 2010. Meanwhile, the
characteristics of cardiovascular disease trials revealed two trends, a tendency toward early-
Investigator-Initiated Trials in Japan
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Table 3. Characteristics of Investigator Initiated Trials Registered in Japan from 2004 to 2012.
Number of IIT (%) (n = 56)
Study Type Interventional 55 (98.2)
Observational 1 (1.8)




Phase Phase 1 4 (7.1)
Phase 1/2 5 (8.9)
Phase 2 19 (33.9)
Phase 2/3 9 (16.1)
Phase 3 12 (21.4)
Phase 4 0 (0.0)
Not speciﬁed 7 (12.5)








Trial Age Group Children (0–17) 7 (12.5)
Children and Adults (0–65) 1 (1.8)
Children, Adults and Older adults (0–75) 21 (37.5)
Adults (20–65) 9 (16.1)
Adults and Older adults (20–84) 15 (26.8)
Older adults (66+y) 0 (0.0)
All ages 2 (3.6)
Missing 1 (1.8)
Trial Masking Open-label 42 (75.0)
Single-blind 4 (7.1)
Double-blind 10 (17.9)










Trial Allocation Randomized 20 (35.7)
Non-randomized 35 (62.5)
Missing 1 (1.8)
Trial Control Placebo Control 7 (12.5)
Active Control 6 (10.7)
(Continued)
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phase trials and/or feasibility studies, similar to the other two areas, and a trend toward obser-
vational trials with> 500 participants and the use of active controls.
In Japan, the number of IITs (56 trials over the 8-year study period) was quite a bit smaller
than those registered in ClinicalTrials.gov. Japanese IITs were dominated by interventional
treatment studies in early phase with few participants. About 20% of IITs were late-phase stud-
ies with more than 100 participants. Japanese IITs were mostly characterized by open-label,
single group, non-randomized, and uncontrolled studies, meaning that the IITs in Japan were
focused on more exploratory and feasible studies than those in the other countries. However,
this conclusion is based on only about 60 trials beginning in 2004; more long-term observation
studies are needed. Overall, most Japanese IITs were early phase and small trials. This charac-
teristic appears no different to IITs in ClinicalTrials.gov. Nevertheless, there is a large differ-
ence in the number of IITs between Japan and other countries. No single factor that is likely to
affect the number of Japanese IITs was found in this study. Some reasons for the low number
of IITs are thought to include few funding opportunities and a poor quality assurance structure
Table 3. (Continued)
Number of IIT (%) (n = 56)
Dose Comparison 6 (10.7)
Historical Control 4 (7.1)
Uncontrolled 33 (58.9)
Sex Female Only 7 (12.5)
Male Only 3 (5.4)
Both 46 (82.1)
doi:10.1371/journal.pone.0148455.t003
Fig 5. Cross-analyses between trial purpose and phase in Japanese registries.Curve areas represent
the number of trials across the phase and the trial purposes.
doi:10.1371/journal.pone.0148455.g005
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[3,8]; however it is the author’s opinion that the cause fundamentally lies within the clinical
trial system in Japan. The number of Japanese IITs could be increased by improving the clinical
trial environment or key areas within academia.
Fig 6. Cross-analyses between trial purpose and participants in Japanese registries.Curve areas
represent the number of trials across participants and the trial purposes.
doi:10.1371/journal.pone.0148455.g006
Fig 7. Cross-analyses between trial participants and phase in Japanese registries. Curve areas
represent the number of trials across phase and the participants.
doi:10.1371/journal.pone.0148455.g007
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The first area in which Japan must improve is its clinical trial system. There are actually two
IIT systems in Japan, one for IND and another for non-IND trials. IND trials are undertaken
in accordance with GCP, with an IND application submitted to the MHLW. These trials are
regulated and monitored in the same way as commercial trials and are reported monthly to the
Institutional Review Board and the Pharmaceuticals and Medical Devices Agency in cases of
safety issues. With few professionals available to operate clinical trials, such requirements pres-
ent large hurdles for academia to overcome because they are often time-consuming and involve
much paperwork and high costs. By contrast, non-IND trials are conducted under the Guide-
lines for Clinical Research issued by the MHLW in 2003, which do not require submission of
an application [9]. The requirements for conducting non-IND IITs are not as stringent as
those for IND trials; however, annual reporting to the research ethics committee is required, as
well as to the MHLW for safety issues. Nevertheless, these requirements involve less time, less
paperwork, and lower cost than IND trials. It is therefore easier for academic institutions to
conduct non-IND trials, even with few staff, which has resulted in over 18,000 non-IND trials,
according to the UMIN-CTR, since its establishment in 2005 [10]. The current environment is
likely one reason for the small number of IITs for IND. However, non-IND trials are not per-
formed in line with GCP. Therefore, the data from non-IND trials are not valid for new indica-
tions for approved drugs because of poorer data quality, owing to the less stringent
requirements for non-IND trials regarding paperwork, research processes, and quality assur-
ance. Conducting non-IND trials might provide some new evidence, but it is not useful in clini-
cal practice.
Therefore, non-IND trials that do not follow GCP should be closed down immediately, and
a review of the current Japanese IND-type IIT system should be carried out, with the aim to
make it more efficient thereby simplifying the conduct of IND trials. Such actions could greatly
improve the current clinical trial situation in Japan by increasing the number of IND-type IITs
performed, through eliminating the need for clinical trial experts and the involvement of regu-
latory authorities. Before such implementation, however, effective ways to reduce paperwork,
costs, and the time required to address regulatory issues must be considered. The Japanese gov-
ernment has created several national programs to build support institutions within academia
that provide clinical trial services such as data management, statistical analysis, and monitor-
ing. These programs could also be helpful for investigators in conducting IND trials [11–14].
There are some limitations in this study. One is that there were some missing data despite
mandatory data requirements by ClinicalTrials.gov and the Japanese registries. Recent reports
have described that the ClinicalTrials.gov database could contain some quality issues owing to
self-reporting by sponsors [15]. Another limitation is the focus only on 1-year characteristics
of A&G trials registered in ClinicalTrials.gov by sponsors from all over the world. In addition,
there were too few Japanese IITs to clearly demonstrate trial characteristics. The EudraCT
database was not open to the public at the time this article was written; therefore, trial charac-
teristics in European countries were unavailable. A comparison that includes European regis-
tries should be made in the near future.
Conclusion
In this study, new and revised clinical trials sponsored by A&G that were registered in
ClinicalTrials.gov during 2010 averaged about 40% of all sponsor-identified trials. According
to analysis of the three main therapeutic areas, these A&G trials were nearly all early phase
studies for the purpose of treatment, with a small number of participants. There were around
60 Japanese IITs over an 8-year period beginning in 2004. These trials were also mostly early-
phase studies for the purpose of treatment, with a small number of participants. The
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characteristics of IITs between Japan and other countries exhibited no great differences,
although there was a large difference in the number of Japanese IITs compared with other
countries. Japan’s IIT system and clinical trial environment should be immediately reviewed,
to close this gap.
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